Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas

Patel, Natalie; Barbieri, Andrea; Gibson, Joanna

doi:10.1016/j.path.2019.08.007

Cited by 27 publications

(16 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating suPAR has recently been associated with chronic kidney disease and elevated suPAR serum levels were suggested to predict impaired renal function after cardiac surgery [ 26 , 27 , 28 ]. Hence, we evaluated if circulating levels of suPAR might be indicative for kidney injury in our cohort of patients.…”

Section: Resultsmentioning

confidence: 99%

“…Interestingly, serum levels of suPAR were significantly higher in patients with elevated serum creatinine concentrations ( Figure 3A) and both parameters demonstrated a significant correlation according to Spearman rank correlation analysis ( Figure 3B). Circulating suPAR has recently been associated with chronic kidney disease and elevated suPAR serum levels were suggested to predict impaired renal function after cardiac surgery [26][27][28]. Hence, we evaluated if circulating levels of suPAR might be indicative for kidney injury in our cohort of patients.…”

Section: Supar Serum Concentrations Are Not Associated With Disease Cmentioning

confidence: 99%

See 1 more Smart Citation

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies

Özdirik

Stueven

Knorr

et al. 2020

JCM

View full text Add to dashboard Cite

Neuroendocrine neoplasia (NEN) comprises heterogeneous tumors that are challenging to diagnose and, especially in cases of poorly differentiated (G3) NEN, are associated with very limited survival. Novel biomarkers allowing an early diagnosis as well as an optimal selection of suitable treatment options are urgently needed to improve the outcome of these patients. Recently, alterations of soluble urokinase-type plasminogen activator receptor (suPAR) serum levels were described in various types of cancers. However, the role of circulating suPAR as a biomarker in patients with NEN is unknown. In this study, we measured suPAR serum levels in a large and well-characterized cohort of 187 patients with NEN (neuroendocrine carcinomas (NEC) n = 30; neuroendocrine tumors (NET), n = 157) as well as 44 healthy controls. suPAR concentrations were significantly elevated in patients compared to controls. However, suPAR concentrations were independent of tumor-related factors such as the proliferation activity according to Ki-67, tumor grading, TNM (TNM classification of malignant tumors) stage, somatostatin receptor expression or clinical features such as functional or nonfunctional disease and the presence of tumor relapse. Interestingly, suPAR concentrations in NET patients were similar when compared to those measured in NEC patients. In contrast to previous results from other malignancies, in our analysis suPAR levels were not a significant predictor of overall survival. In conclusion, our data suggests that suPAR serum concentrations are elevated in NEN patients but do not allow prediction of outcome.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Supar Serum Concentrations Are Not Associated With Disease Cmentioning

confidence: 99%

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies

Özdirik

Stueven

Knorr

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…According to the population-based study using nationally representative data from the Surveillance, Epidemiology, and End Results (SEER) program, the incidence, and prevalence of GEP-NEN are steadily rising, particularly in the small intestine, followed by rectum, appendix, colon, and stomach [7,8]. A 12-year study from Lebanon's single-center Institute showed that G-NEN accounted for about 18%, second only to pancreatic neuroendocrine tumors [9].…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Features and Prognosis of Gastric Neuroendocrine Neoplasms

Wang

Wen

Tian

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Purpose: We performed a retrospective study to investigate the relationship between clinicopathological features and prognosis of G-NEN.Methods: Clinicopathological features and follow-up data of 67 patients with G-NEN treated at Shandong Provincial Hospital affiliated of Shandong University were analyzed retrospectively. Results: This whole cohort included 53 males and 14 females, with a mean age of 59.37±9.80 years. The clinical symptoms and the primary tumor site were not specific. Neuroendocrine tumor, neuroendocrine carcinoma, and mixed neuroendocrine–non‐neuroendocrine neoplasm accounted for 14.93%, 59.70%, and 25.37%, respectively. TNM stages Ⅰ-Ⅳ: 6, 6, 49, 4, respectively. All patients underwent surgically treated. Forty-five patients underwent laparoscopic surgery, and twenty-two patients received an open approach. The median survival time was 36 months in all patients. The overall survival rate for the entire cohort was 68.1 %, 44.7 %, and 34.5% at 1, 3, and 5 years, respectively. Logistic regression analysis revealed that the invasive depth of tumors was predictors for metastasis. The univariate analysis confirmed that smoking, T stage, distant metastasis, and surgical method were related to survival. COX regression analysis showed that the T stage (HR=4.817, 95%CI: 1.021-22.729, P=0.047) was an independent risk factor for evaluating the prognosis of patients with G-NEN.Conclusions: G-NEN is a kind of rare tumors that can occur at any part of the stomach. The clinical features are not specific. The tumor invasive depth related to tumor metastasis. The prognosis is associated with smoking, T stage, distant metastasis, and surgical method. Of them, T stage is an independent prognostic factor for G-NEN patients. But larger studies are needed in the future.

show abstract

“…Neuroendocrine cells are epithelioid cells that develop from gastrointestinal (GI) stem cells rather than neurocrest[ 24 ]. There have been exciting developments regarding NET biology in recent years.…”

Section: Biology Biomarkers and Molecular Pathogenesis Of Netsmentioning

confidence: 99%

Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours

Yozgat¹,

Kekilli²,

Altay³

2021

WJCC

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) are a rare and heterogeneous disease group and constitute 0.5% of all malignancies. The annual incidence of NETs is increasing worldwide. The reason for the increase in the incidence of NETs is the detection of benign lesions, incidental detection due to the highest use of endoscopic and imaging procedures, and higher recognition rates of pathologists. There have been exciting developments regarding NET biology in recent years. Among these, first of all, somatostatin receptors and downstream pathways in neuroendocrine cells have been found to be important regulatory mechanisms for protein synthesis, hormone secretion, and proliferation. Subsequently, activation of the mammalian target of rapamycin pathway was found to be an important mechanism in angiogenesis and tumor survival and cell metabolism. Finally, the importance of proangiogenic factors (platelet-derived growth factor, vascular endothelial growth factor, fibroblastic growth factor, angiopoietin, and semaphorins) in the progression of NET has been determined. Using the combination of biomarkers and imaging methods allows early evaluation of the appropriateness of treatment and response to treatment.

show abstract

Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas

Cited by 27 publications

References 116 publications

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies

Clinicopathological Features and Prognosis of Gastric Neuroendocrine Neoplasms

Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours

Contact Info

Product

Resources

About